Can contrast-enhanced ultrasound with perfluorobutane add value in detection of hepatocellular carcinoma in cirrhosis during surveillance?

Affiliations

¹ Liver Unit and Interventional Ultrasound Unit, Athena Clinical Institute, Piedimonte Matese (CE), Caserta, Italy.
² Liver Unit, Cardarelli Hospital, Largo A Cardarelli, Naples, Italy.
³ Internal Medicine Unit, Brindisi General Hospital, Brindisi, Italy.
⁴ Radiation Oncology Unit, Campus Biomedico, Rome, Italy.
⁵ Fondazione Policlinico A. Gemelli IRCCS, Department of Woman and Child Health and Public Health, Largo A Gemelli, Roma, Italy.

Editorial

Antonio Giorgio et al. Quant Imaging Med Surg. 2019 Aug.

. 2019 Aug;9(8):1466-1469.

doi: 10.21037/qims.2019.07.10.

¹ Liver Unit and Interventional Ultrasound Unit, Athena Clinical Institute, Piedimonte Matese (CE), Caserta, Italy.
² Liver Unit, Cardarelli Hospital, Largo A Cardarelli, Naples, Italy.
³ Internal Medicine Unit, Brindisi General Hospital, Brindisi, Italy.
⁴ Radiation Oncology Unit, Campus Biomedico, Rome, Italy.
⁵ Fondazione Policlinico A. Gemelli IRCCS, Department of Woman and Child Health and Public Health, Largo A Gemelli, Roma, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN).
Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, Han K, Nam CM, Park SH, Lee KH. Park JH, et al. Radiology. 2019 Sep;292(3):638-646. doi: 10.1148/radiol.2019190183. Epub 2019 Jul 9. Radiology. 2019. PMID: 31287387

1. Soresi M, Terranova A, Licata A, Serruto A, Montalto G, Brancatelli G, Giannitrapani L. Surveillance program for diagnosis of HCC in liver cirrhosis: role of ultrasound echo patterns. Biomed Res Int 2017;2017:4932759. 10.1155/2017/4932759 - DOI - PMC - PubMed
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
1. Maringhini A, Cottone M, Sciarrino E, Marcenò MP, La Seta F, Rinaldi F, Pagliaro L. Ultrasonographic and radionuclide detection of hepatocellular carcinoma in cirrhotics with low alpha-fetoprotein levels. Cancer 1984;54:2924-6. 10.1002/1097-0142(19841215)54:12<2924::AID-CNCR2820541218>3.0.CO;2-F - DOI - PubMed
1. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol 2019;25:1550-9. 10.3748/wjg.v25.i13.1550 - DOI - PMC - PubMed
1. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70. 10.1007/s12072-017-9799-9 - DOI - PMC - PubMed